• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Global Acquisitions Heat Up

Global Acquisitions Heat Up

April 27, 2009
CenterWatch Staff

Three companies—Phase Forward, Chiltern International and ChemDiv—are the latest clinical trial companies to complete global acquisitions.

eClinical company Phase Forward acquired Waban Software, a Cambridge, Mass.-based clinical data analysis and reporting company with operations in Mumbai, India; UK-based contract research organization (CRO) Chiltern acquired Vigiun, a CRO in São Paulo, Brazil; and San Diego, Calif.-based ChemDiv (a contract research discovery and development organization) purchased Russian CRO Prudentas.

Phase Forward purchased Waban for $14 million in cash to meet a “growing demand from life sciences companies to streamline the link between data management and biostatistics activities,” according to Phase Forward chairman and CEO Bob Weiler.

Waban, now the Waban Software Group within Phase Forward, generated approximately $4 million in revenue and broke even during the full year 2008, according to a Phase Forward release. Phase Forward’s Waltham, Mass., headquarters will become the local headquarters for Waban, which has 81 employees worldwide. Current Waban president Himanshu Oberoi, Ph.D., will become vice president, Waban Software Group, Phase Forward.

Phase Forward’s full-year 2008 GAAP revenues were $170.2 million, and as of December 31, 2008, the company had 718 employees, according to Phase Forward’s 2008 annual report.

Chiltern International acquired Vigiun for an undisclosed amount. Chiltern began operating in Latin America a year ago in Argentina, but the Vigiun deal will strengthen the company’s presence in the region, said John Vann, Chiltern’s executive vice president, Americas. Chiltern now has offices in Brazil, Argentina, India, the UK and the United States.

Vigiun specializes in infectious disease, oncology and respiratory and was founded in 1999 by Eduardo Forleo, M.D., and Elisa Halker. Forleo will stay on as Chiltern’s country manager for Brazil and medical director for Latin America, and Halker will serve as director of clinical operations for Brazil.

“This is an exciting time to become a part of Chiltern. Our business has grown to the point that it makes sense to join forces with a global CRO whose mission and values align with ours. I look forward to contributing in very positive ways to the company’s ongoing and future success,” Forleo said in a company statement.

Chiltern had sales of $33.2 million in 2008 and has 255 employees, according to Dun and Bradstreet.

In another recent acquisition, ChemDiv purchased Russian CRO Prudentas for an undisclosed sum, and will continue to operate the company under the Prudentas name as a ChemDiv Group company.

The Prudentas acquisition comes in response to ChemDiv’s clients’ growing interest in conducting clinical trials, according to a ChemDiv statement. The two companies had previously worked together, and Prudentas had established itself as an “experienced, professional and reliable CRO collaborator,” said the company release.

“Our decision to make this investment capitalizes on the growing trend of conducting clinical trials in Eastern Europe; based on the availability of naive patient populations, rapid and efficient trial recruitment and high data quality across a broad range of therapeutic indications,” said ChemDiv president and CEO Nikolay Savchuk. “Prudentas will help us bring unique levels of clinical development productivity to pharma and biotech partners through risk mitigation, cost- and time-savings. This acquisition further strengthens and expands our global presence specifically in the Eastern European and Eurasian markets and responds to growing customer demand for comprehensive R&D outsourcing.”

ChemDiv had sales of $56.4 million in 2008 and has 400 employees, according to Dun and Bradstreet.

The acquisition was completed through ChemDiv’s ChemRar High-Tech Center, a biopharmaceutical complex housing life science R&D organizations in Moscow, Russia. The companies within the Center discover, develop and commercialize drugs for partners in Russia and worldwide, according to a company description.

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing